You are here

P&T® Journal contents for March 2009

Features

Patients who need enteral nutrition may also require PPIs for acid suppression. The currently available and most widely prescribed PPIs are reviewed, along with their routes of delivery in nasogastric, gastrostomy, and jejunal feeding tubes.
Terri M. Wensel, PharmD
Commentary
Emerging Trends in the Blogosphere
Even pharmaceutical companies, which have long shied away from blogging on the Internet, understand that the conventional static Web site is just not good enough any more. Will future pharma bloggers be able to incorporate the real-time engagement and transparency that are needed?
Miriam Reisman
Meeting Highlights
If approved by the FDA, the platelet inhibitor prasugrel will be a first-in-its-class competitor of clopidogrel (Plavix). The new drug is designed to reduce the risk of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular disease, but bleeding and the risk of neoplasms can result.
Walter Alexander
Topics include milnacipran (Savella) tablets for fibromyalgia, calcitriol ointment (Vectical) for plaque psoriasis, and degarelix subcutaneous injection, a hormone for treating advanced prostate cancer.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David B. Nash, MD, MBA, discusses evidence-based case rates, the building blocks of a new payment model that aims to support a patient-centered health environment.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, recommends rest periods, off-duty time, naps, meal breaks, and other safety practices to prevent fatigue in health care workers, thereby minimizing the potential for mistakes on the job.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses how the FDA under the Obama administration might deal with off-label drug promotion for unapproved uses.
Stephen Barlas
From ATryn to Tindamax, P&T presents the latest information about FDA approvals, indications, recalls, and updates.
Drug Forecast
Drs. Kapur and Bonk review rilonacept (Arcalyst) for treating cryopyrin-associated periodic syndromes.
Saloni Kapur, PharmD, MPA, and Mary Ellen Bonk, PharmD